{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:40:17Z","timestamp":1773279617528,"version":"3.50.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Progressive myoclonic epilepsies (PMEs) are a heterogenous group of genetic diseases presenting with epilepsy, cognitive impairment, and severe action myoclonus, which can severely affect daily life activities and independent walking ability. Perampanel is a recent commercially available antiseizure medication with high efficacy against generalized seizures. Some reports supported the role of perampanel in ameliorating action myoclonus in PMEs. Here, we aimed to describe a case series and provide a systematic literature review on perampanel effects on PMEs.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We report the perampanel effectiveness on myoclonus, daily life activities, and seizures on an original Italian multicenter case series of 11 individuals with PMEs. Then, using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, we performed a systematic review on perampanel effect on myoclonus and disability in PMEs. We searched PubMed, Scopus, and Google Scholar articles on perampanel and PMEs up to June 2020. No prospective trials were found. We reviewed 11 case series manuscripts reporting 104 cases of different PMEs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Here, we are reporting the effectiveness of perampanel in five individuals affected by Unverricht\u2013Lundborg disease, three by Lafora disease, two by sialidosis, and one by an undetermined PME. Nine out of 11 individuals improved their disability related to the action myoclonus (two with Lafora disease did not). Among the 104 persons with PMEs collected by the systematic review, we found that more than half of the patients receiving perampanel exhibited an amelioration of action myoclonus and, consequently, of their independence in daily life activities. The Unverricht\u2013Lundborg disease seemed to show the best clinical response to perampanel, in comparison with the other more severe PMEs. A significant seizure reduction was achieved by almost all persons with active epilepsy. Only 11% of PME patients dropped out due to inefficacy.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Perampanel demonstrated a beneficial effect with regard to action myoclonus, disability, and seizures and was well-tolerated in people with PMEs, independently from their genetic diagnosis. Given the limited scientific evidence, broader prospective trials should be encouraged.<\/jats:p>","DOI":"10.3389\/fneur.2021.630366","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T06:33:16Z","timestamp":1616567596000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Perampanel Improves Cortical Myoclonus and Disability in Progressive Myoclonic Epilepsies: A Case Series and a Systematic Review of the Literature"],"prefix":"10.3389","volume":"12","author":[{"given":"Giovanni","family":"Assenza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristofaro","family":"Nocerino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Tombini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"D'Aniello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Marrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Lanzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Di Lazzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonilda","family":"Bilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonietta","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci10080506","article-title":"Diagnosis and management of type 1 sialidosis: Clinical insights from long-term care of four unrelated patients","volume":"10","author":"Coppola","year":"2020","journal-title":"Brain Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1684\/epd.2016.0861","article-title":"Myoclonus and seizures in progressive myoclonus epilepsies: pharmacology and therapeutic trials","volume":"18","author":"Michelucci","year":"2016","journal-title":"Epileptic Disord"},{"key":"B3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.seizure.2019.08.012","article-title":"The best evidence for progressive myoclonic epilepsy: a pathway to precision therapy","volume":"71","author":"Orsini","year":"2019","journal-title":"Seizure"},{"key":"B4","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.0013-9580.2004.56902.x","article-title":"Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations","volume":"45","author":"Magaudda","year":"2004","journal-title":"Epilepsia."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"106191","DOI":"10.1016\/j.eplepsyres.2019.106191","article-title":"An Italian multicentre study of perampanel in progressive myoclonus epilepsies","volume":"156","author":"Canafoglia","year":"2019","journal-title":"Epilepsy Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.clinph.2019.07.006","article-title":"Low-dose perampanel improves refractory cortical myoclonus by the dispersed and suppressed paroxysmal depolarization shifts in the sensorimotor cortex","volume":"130","author":"Oi","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/epi.13662","article-title":"Perampanel in 12 patients with Unverricht-Lundborg disease","volume":"58","author":"Crespel","year":"2017","journal-title":"Epilepsia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.yebeh.2016.06.041","article-title":"Efficacy and tolerability of perampanel in ten patients with Lafora disease","volume":"62","author":"Goldsmith","year":"2016","journal-title":"Epilepsy Behav"},{"key":"B11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ebcr.2014.09.003","article-title":"Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel","volume":"2","author":"Dirani","year":"2014","journal-title":"Epilepsy Behav Case Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ebcr.2018.02.005","article-title":"Seizure remission and improvement of neurological function in sialidosis with perampanel therapy","volume":"10","author":"Hu","year":"2018","journal-title":"Epilepsy Behav Case Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"622","DOI":"10.5692\/clinicalneurol.cn-001179","article-title":"Low-dose perampanel improved cortical myoclonus and basophobia in a patient with Unverricht-Lundborg disease: a case report","volume":"58","author":"Oi","year":"2018","journal-title":"Rinsho Shinkeigaku."},{"key":"B14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ebcr.2013.07.003","article-title":"Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease)","volume":"1","author":"Schorlemmer","year":"2013","journal-title":"Epilepsy Behav Case Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ebcr.2017.05.004","article-title":"Efficacy of perampanel for controlling seizures and improving neurological dysfunction in a patient with dentatorubral\u2013pallidoluysian atrophy (DRPLA)","volume":"8","author":"Shiraishi","year":"2017","journal-title":"Epilepsy Behav Case Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.braindev.2019.05.001","article-title":"Perampanel attenuates myoclonus in a patient with neuronal ceroid lipofuscinoses type 2 disease","volume":"41","author":"Wong","year":"2019","journal-title":"Brain Dev"},{"key":"B17","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.seizure.2020.06.011","article-title":"Adjunctive perampanel and myoclonic and absence seizures: post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy","volume":"80","author":"Brandt","year":"2020","journal-title":"Seizure"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1111\/j.1528-1167.2012.03718.x","article-title":"Electroclinical presentation and genotype-phenotype relationships in patients with Unverricht-Lundborg disease carrying compound heterozygous CSTB point and indel mutations","volume":"53","author":"Canafoglia","year":"2012","journal-title":"Epilepsia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1111\/epi.13626","article-title":"A novel c132-134del mutation in Unverricht-Lundborg disease and the review of literature of heterozygous compound patients","volume":"58","author":"Assenza","year":"2017","journal-title":"Epilepsia"},{"key":"B20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1528-1157.2000.tb01727.x","article-title":"Analysis of the \u201choneymoon effect\u201d in adult epilepsy patients","volume":"41","author":"Boggs","year":"2000","journal-title":"Epilepsia"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1684\/epd.2016.0835","article-title":"Neurophysiology of myoclonus and progressive myoclonus epilepsies","volume":"18","author":"Avanzini","year":"2016","journal-title":"Epileptic Disord"},{"key":"B22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0013-4694(98)00058-3","article-title":"Neurophysiology of positive and negative myoclonus","volume":"107","author":"Tassinari","year":"1998","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/mds.23673","article-title":"Milestones in myoclonus","volume":"26","author":"Shibasaki","year":"2011","journal-title":"Mov Disord"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.clinph.2020.05.022","article-title":"The effects of antiepileptic drugs on high-frequency oscillations in somatosensory evoked potentials","volume":"131","author":"Lanzone","year":"2020","journal-title":"Clin Neurophysiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.clinph.2019.10.017","article-title":"Thalamo-cortical network dysfunction in temporal lobe epilepsy","volume":"131","author":"Assenza","year":"2020","journal-title":"Clin Neurophysiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1528-1157.1992.tb01704.x","article-title":"Somatosensory evoked potentials in juvenile myoclonic epilepsy","volume":"33","author":"Salas-Puig","year":"1992","journal-title":"Epilepsia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.clinph.2020.04.164","article-title":"Thalamic and cortical hyperexcitability in juvenile myoclonic epilepsy","volume":"131","author":"Assenza","year":"2020","journal-title":"Clin Neurophysiol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.clinph.2019.01.005","article-title":"Cortical inhibitory dysfunction in epilepsia partialis continua: a high frequency oscillation somatosensory evoked potential study","volume":"130","author":"Insola","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.clinph.2020.12.030","article-title":"Effects of the noncompetitive AMPA receptor antagonist perampanel on thalamo-cortical excitability: A study of high-frequency oscillations in somatosensory evoked potentials","volume":"132","author":"Lanzone","year":"2021","journal-title":"Clin Neurophysiol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.630366\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T06:33:18Z","timestamp":1616567598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.630366\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":29,"alternative-id":["10.3389\/fneur.2021.630366"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.630366","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"article-number":"630366"}}